Monte Rosa reports Phase 1 data for MRT-8102 in cardiovascular risk study
The company said its NEK7 degrader lowered multiple inflammatory markers tied to atherosclerosis and plans three Phase 2 trials starting as early as late 2026.
SEC filing
Latest
4 stories
Today
Tuesday, September 8
Novartis starts Phase 2 trial of Monte Rosa's MRT-6160 in Sjögren's disease
Novartis initiated a Phase 2a/b study of the VAV1-directed molecular glue degrader, triggering a $50 million milestone payment to Monte Rosa under their license agreement.
SEC filing
Thursday, August 6
Monte Rosa reports Q2 2026 results as MGD pipeline advances on three fronts
Monte Rosa completed enrollment in its MRT-8102 cardiovascular study, activated two other Phase 2 trials, and said cash on hand should fund operations into 2029.
SEC filing